Last reviewed · How we verify

5-fluoro-2-deoxycytidine

City of Hope Medical Center · Phase 1 active Small molecule

Inhibits thymidylate synthase

Inhibits thymidylate synthase Used for Colorectal cancer.

At a glance

Generic name5-fluoro-2-deoxycytidine
Also known asFdCyd
SponsorCity of Hope Medical Center
Drug classNucleoside analog
TargetThymidylate synthase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 1

Mechanism of action

5-fluoro-2-deoxycytidine is a thymidylate synthase inhibitor that works by interfering with DNA synthesis, leading to cell death in rapidly dividing cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: